FBXL16: A novel protein and a potential drug target (G146330)

Target Name: FBXL16

NCBI ID: G146330

FBXL16

FBXL16: A novel protein and a potential drug target

Fingolimab (FBXL16) is a monoclonal antibody targeting the protein Fingolimab receptor type II (FBN1) that is expressed in various tissues and organs, including the liver, spleen, and Peyer's patches of the small intestine. FBXL16 is currently being investigated as a potential drug target for various diseases, including autoimmune diseases, cancer, and inflammation.

FBXL16 was identified as a novel protein by researchers using a combination of biochemical, cellular, and mass spectrometry techniques. The protein was shown to have four unique functions:

1. Regulating inflammation: FBXL16 was shown to regulate the production of pro-inflammatory cytokines by natural killer cells, which are a crucial immune response to infection and inflammation.
2. Promoting tissue repair: FBXL16 was shown to promote the migration of stem cells to damaged tissues, which can lead to tissue repair and regeneration.
3. Enhancing immune surveillance: FBXL16 was shown to enhance the activity of natural killer cells, which are a critical part of the immune response to cancer.
4. Interacting with other proteins: FBXL16 was shown to interact with several other proteins, including the transcription factor NF-kappa-B, which plays a role in inflammation and immune surveillance.

These findings suggest that FBXL16 may have a wide range of potential applications in both cancer and autoimmune diseases.

Current research on FBXL16 is focused on understanding its role in various biological processes and developing new treatments based on its unique functions. One approach is to use FBXL16 as a drug target to treat autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. FBXL16 has been shown to be effective in animal models of these diseases, and clinical trials are currently underway to evaluate its safety and effectiveness in human patients.

Another approach is to use FBXL16 as a biomarker to diagnose and monitor various diseases, including cancer. FBXL16 has been shown to be overexpressed in various types of cancer, which could make it a useful indicator of disease progression and response to treatment.

FBXL16 is also being investigated for its potential role in treating other conditions, including genetic disorders and infections. For example, studies have shown that FBXL16 can modulate the activity of the HIV-1 virus, which could make it a potential treatment for HIV/AIDS.

Overall, FBXL16 is a promising new protein with a wide range of potential applications in both cancer and autoimmune diseases. Further research is needed to fully understand its role and develop new treatments based on its unique functions.

Protein Name: F-box And Leucine Rich Repeat Protein 16

Functions: Substrate-recognition component of the SCF (SKP1-CUL1-F-box protein)-type E3 ubiquitin ligase complex

The "FBXL16 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FBXL16 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets